Concentrating investment of management resources in “number-one” products and businesses
First written in FY2017. 2 of 5 entries say "Advanced", first in FY2018-Q1. Latest entry: FY2022.
The whole theme swung hardest in 2024: 2 of 8 companies on the "Worse" side.
13 other companies' latest entry also says "Restated".
- FY2022RestatedAnnual report
「The pharmaceutical and chemicals businesses of our group are expected to continue achieving strong growth through global expansion and category selection, and we will continue our existing strategy and deliver reliable results.」
The policy of refining the pharmaceutical and chemicals businesses into niche-leading businesses was continued, with topical drugs, high-potency injectable CDMO services, and chemicals for electronic components and semiconductors reiterated as specific priority areas. - FY2020RaisedAnnual report
「Based on the dermatology field, aim to become the leader in the number of topical drug products and production capacity. Aim to become the leader in high-potency injectable CDMO services meeting global standards. Aim to strengthen and expand the business foundation through the introduction of topical and injectable drugs, joint development of innovative drugs, domestic and overseas business alliances, M&A and other initiatives.」
The previous policy of concentrating on “No. 1” products and businesses was expanded and made more specific to cover the number of topical drug products and production capacity, high-potency injectable CDMO services, product introductions, joint development, alliances and M&A. - FY2018-Q3AdvancedAnnual report
「Our group has announced Vision “i-111” as its medium- to long-term vision toward the fiscal year ending November 2025, when it will mark its 111th anniversary. To achieve this vision, we are considering and implementing various measures in the chemicals business to increase sales, achieve the No. 1 market share and attain ROIC of 10.0%. As one such measure, we will acquire Hitachi Chemical's chemicals business for printed wiring boards.」
The acquisition of Hitachi Chemical's business was carried out toward the Vision “i-111” targets for the fiscal year ending November 2025: sales growth in the chemicals business, the No. 1 market share and ROIC of 10.0%. - FY2018-Q1AdvancedAnnual report
「To achieve this vision, we are considering and implementing various measures in the chemicals business to increase sales, achieve the No. 1 market share and attain ROIC of 10.0%. As one such measure, we will acquire Hitachi Chemical's chemicals business for printed wiring boards.」
The acquisition of Hitachi Chemical's chemicals business was decided as a specific measure toward achieving the No. 1 market share and ROIC of 10.0%. - FY2017First statedAnnual report
「Focusing on “No. 1” products and businesses. While the businesses operated by our group include a number with relatively low market shares, we also have several so-called “No. 1” products and businesses with very strong competitiveness and brand strength in specific markets. We will focus on these strong products and businesses and make concentrated and proactive investments of management resources.」
As one of the four basic strategies of the medium- to long-term vision, concentrated investment of management resources in products and businesses with strong competitiveness and brand strength was explicitly stated for the first time.